Heartburn Clinical Trial
Official title:
A Randomized, Double-blind, Two Period, Crossover Study to Evaluate the Effects of a Single Dose of Itopride 200 mg on Esophageal and Gastric pH and Reflux in Patients With Heartburn
Verified date | February 2017 |
Source | Forest Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effects of itopride in patients with heartburn.
Status | Completed |
Enrollment | 48 |
Est. completion date | December 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Otherwise healthy males and females aged 18-70, with at least 3 episodes of heartburn or acid regurgitation per week. |
Country | Name | City | State |
---|---|---|---|
United States | The Oklahoma Foundation for Digestive Research | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Forest Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 24-hour pH Monitoring | after 5 days of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT00481949 -
Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Recruiting |
NCT02105090 -
Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy
|
Phase 4 | |
Completed |
NCT01338077 -
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
|
Phase 3 | |
Completed |
NCT01005251 -
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
|
Phase 2 | |
Terminated |
NCT00536328 -
What is the Predictive Value of the Reflux Impact Scale
|
N/A | |
Completed |
NCT00236197 -
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
|
Phase 3 | |
Completed |
NCT00236184 -
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
|
Phase 3 | |
Completed |
NCT00236392 -
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
|
Phase 3 | |
Completed |
NCT04153552 -
Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn
|
N/A | |
Recruiting |
NCT06075082 -
The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms.
|
N/A | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Recruiting |
NCT02277886 -
Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances
|
Phase 4 | |
Completed |
NCT01249651 -
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
|
Phase 4 | |
Completed |
NCT00588939 -
Confocal Laser Microscopy in Non Erosive Reflux Disease
|
N/A | |
Completed |
NCT00206024 -
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
|
Phase 4 | |
Recruiting |
NCT05976165 -
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
|
N/A | |
Not yet recruiting |
NCT06098742 -
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers
|
N/A |